亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

贝伐单抗 医学 阿替唑单抗 肿瘤科 结直肠癌 内科学 临床终点 化疗 癌症 无容量 随机对照试验 免疫疗法
作者
Carlotta Antoniotti,Beatrice Borelli,Daniele Rossini,Filippo Pietrantonio,Federica Morano,Lisa Salvatore,Sara Lonardi,Federica Marmorino,Stefano Tamberi,Salvatore Corallo,Giampaolo Tortora,Francesca Bergamo,Di Stefano Brunella,Alessandra Boccaccino,Elisa Grassi,Patrizia Racca,Emiliano Tamburini,Giuseppe Aprile,Roberto Moretto,Luca Boni,Alfredo Falcone,Chiara Cremolini
出处
期刊:BMC Cancer [BioMed Central]
卷期号:20 (1) 被引量:43
标识
DOI:10.1186/s12885-020-07169-6
摘要

Abstract Background Immune checkpoint inhibitors (ICIs) reported remarkable achievements in several solid tumours. However, in metastatic colorectal cancer (mCRC) promising results are limited to patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-high) tumours due to their immune-enriched microenvironment. Combining cytotoxic agents and bevacizumab in mCRC with proficient mismatch repair/microsatellite stability (pMMR/MSS) could make ICIs efficacious by increasing the exposure of neoantigens, especially with highly active chemotherapy regimens, inducing immunogenic cell death, increasing the tumoral infiltration of CD8+ T-cells and reducing tumour-associated myeloid-derived suppressor cells. VEGF-blockade also plays an immunomodulatory role by inhibiting the expansion of T regulatory lymphocytes. Consistently with this rationale, a phase Ib study combined the anti-PDL-1 atezolizumab with FOLFOX/bevacizumab as first-line treatment of mCRC, irrespective of microsatellite status, and reported interesting activity and efficacy results, without safety concerns. Phase III trials led to identify FOLFOXIRI plus bevacizumab as an upfront therapeutic option in selected mCRC patients. Drawing from these considerations, the combination of atezolizumab with an intensified upfront treatment (FOLFOXIRI) and bevacizumab could be worthy of investigation. Methods AtezoTRIBE is a prospective, open label, phase II, comparative trial in which initially unresectable and previously untreated mCRC patients, irrespective of microsatellite status, are randomized in a 1:2 ratio to receive up to 8 cycles of FOLFOXIRI/bevacizumab alone or in combination with atezolizumab, followed by maintenance with bevacizumab plus 5-fluoruracil/leucovorin with or without atezolizumab according to treatment arm until disease progression. The primary endpoint is PFS. Assuming a median PFS of 12 months for standard arm, 201 patients should be randomized in a 1:2 ratio to detect a hazard ratio of 0.66 in favour of the experimental arm. A safety run-in phase including the first 6 patients enrolled in the FOLFOXIRI/bevacizumab/atezolizumab arm was planned, and no unexpected adverse events or severe toxicities were highlighted by the Safety Monitoring Committee. Discussion The AtezoTRIBE study aims at assessing whether the addition of atezolizumab to an intensified chemotherapy plus bevacizumab might be an efficacious upfront strategy for the treatment of mCRC, irrespective of the microsatellite status. Trial registration AtezoTRIBE is registered at Clinicaltrials.gov ( NCT03721653 ), October 26th, 2018 and at EUDRACT (2017–000977-35), Februray 28th, 2017 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
6秒前
A水暖五金批发张哥完成签到,获得积分10
6秒前
Ni完成签到 ,获得积分10
7秒前
云墨完成签到 ,获得积分10
7秒前
8秒前
椰子云发布了新的文献求助10
10秒前
学术雷锋发布了新的文献求助10
13秒前
Moon完成签到 ,获得积分10
17秒前
天真的乐驹完成签到 ,获得积分10
21秒前
李健的小迷弟的应助被郦稀采纳,获得10
21秒前
Moon关注了科研通微信公众号
21秒前
22秒前
乐康完成签到,获得积分10
22秒前
25秒前
复杂惜珊完成签到,获得积分10
32秒前
cx完成签到,获得积分10
37秒前
机灵伟诚完成签到,获得积分10
37秒前
学霸业的应助被纯情的阁采纳,获得10
39秒前
极限001的应助被纯情的阁采纳,获得50
39秒前
Maestro_S的应助被纯情的阁采纳,获得10
39秒前
Nikkie2411的应助被纯情的阁采纳,获得10
39秒前
42秒前
43秒前
369ninja的应助被科研通管家采纳,获得10
45秒前
丘比特的应助被科研通管家采纳,获得10
45秒前
手打鱼丸完成签到 ,获得积分10
45秒前
45秒前
完美世界的应助被科研通管家采纳,获得10
45秒前
莫名乐乐完成签到,获得积分10
45秒前
FashionBoy的应助被科研通管家采纳,获得10
45秒前
SciGPT的应助被科研通管家采纳,获得10
45秒前
Akim的应助被纯情的阁采纳,获得10
45秒前
null的应助被科研通管家采纳,获得10
45秒前
46秒前
隐形曼青的应助被纯情的阁采纳,获得10
46秒前
null的应助被科研通管家采纳,获得10
46秒前
wanci的应助被科研通管家采纳,获得30
46秒前
大个的应助被纯情的阁采纳,获得30
46秒前
46秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158598
求助须知:如何正确求助?哪些是违规求助? 9554358
关于积分的说明 21719087
捐赠科研通 7748128
什么是DOI,文献DOI怎么找? 3427032
关于科研通互助平台的介绍 2551902
邀请新用户注册赠送积分活动 2471277